First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors
News
iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with ... Read more